Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
This is a single-center, prospective, single-arm clinical trial to evaluate the efficacy and safety of Huaier granules in combination with immunotargeted agents in postoperative patients with ovarian cancer.
Ovarian Cancer
DRUG: Huaier granule
Progression Free survival (PFS), PFS according to the RECIST 1.1 criteria, based on the investigator's assessment., up to 2 years from start of treatment
Median Progression Free survival, mPFS is defined as the median time from study entry to date of first documented objective tumor recurrence according to RECIST 1.1, Every 3 month until 2 years from start of treatment|1-year progression-free survival rate, The time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) or death from any cause, up to 1 years|Median overall survival, Median observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol, Every 3 month until 2 years from start of treatment|1 year overall survival rate, Observed length of life from entry into the study to death; or for living patients, the date of last contact regardless of whether or not this contact is on a subsequent protocol., 1 year|overall survival, OS is defined as the time from start of treatment to date of death due to any cause, or last patient contact, From study entry to death or last contact, up to 2 years of follow-up|Quality of life score（ EQ-5D）, questionnaires to be completed by patients and collected frequently during the trial, Every 3 month until 2 years from start of treatment|Quality of life score（EORTC-QLQ-OV28）, Assessment of quality of life according to the QLQ-OV28/EORTC scales, Every 3 month until 2 years from start of treatment|Quality of life score（EORTC-QLQ-C30）, Assessment of quality of life according to the QLQ-C30/EORTC scales, Every 3 month until 2 years from start of treatment|Quality of life score（FACT-O）, The FACT-O questionnaire consists of a Physical Well-Being Section, Social/Family Well-Being Section, Emotional Well-Being Section, Functional Well-Being Section, and Additional Concerns Section, Every 3 month until 2 years from start of treatment|the rates of AEs and SAEs, frequency of adverse events according to MedDRA terms, up to 2 years
Primary objective :

1) To evaluate the efficacy of Huaier granule combined with immunotargeted drugs in the treatment of postoperative ovarian cancer patients

Secondary objectives:

1)To analyze the safety of Huaier granule in the treatment of postoperative ovarian cancer patients; 2)2) To analyze the influence of Huaier granule on postoperative quality of life of patients with ovarian cancer.